Mercaptopurine Therapy in Ulcerative Colitis

Last updated: January 6, 2020
Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Overall Status: Active - Recruiting

Phase

3

Condition

Inflammatory Bowel Disease

Crohn's Disease

Treatment

N/A

Clinical Study ID

NCT02910245
SA652012
  • Ages 18-80
  • All Genders

Study Summary

This project is a double-blind, randomized, placebo-controlled, multicenter trial in the Netherlands. The aim of this study is to investigate the therapeutic efficacy of optimized 6-mercaptopurine (6-MP) in ulcerative colitis patients. Therapeutic drug monitoring (TDM) will be performed in order to optimize treatment outcomes and objective endoscopic endpoints will be used.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Confirmed diagnosis of UC by endoscopy and histopathology

  2. Patients between 18 and 80 years of age

  3. Active disease, despite oral treatment with at least 2g/day 5-ASA

  4. Treatment with oral corticosteroids is required

Exclusion

Exclusion Criteria:

  1. Prior treatment with thiopurines

  2. Prior treatment with biologics (e.g. anti-TNF agents and vedolizumab)

  3. Current pregnancy (a pregnancy test will be performed if necessary according to thetreating physician)

  4. Chronic Obstructive Pulmonary Disease (COPD)

  5. Acute coronary heart disease

  6. (Bacterial) gastroenteritis has to be treated first

  7. Coagulation disorders

  8. Active malignancy

  9. History of colonic dysplasia/cancer

  10. Extensive colonic resection, i.e. subtotal colectomy with <15 cm colon in situ

  11. Concomitant therapy with drugs interfering with MP metabolism, like allopurinol,ribavirin or anti-epileptics.

  12. Known systemic fungal infections or parasitic infections have to be treated first

  13. Known duodenal or ventricular ulcus

  14. Substance abuse, such as alcohol (> 80 gram/day - one standard glass contains 10 gramof alcohol), I.V. drugs and inhaled drugs. If the subject has a history of substanceabuse, to be considered for inclusion into the protocol, the subject must haveabstained from using the abused substance for at least 2 years. Subjects receivingmethadone within the past 2 years are also excluded

  15. Positive tuberculosis screen (when a screening is performed at the discretion of thetreating physician)

  16. Active hepatitis B virus or hepatitis C virus infection defined as a positiveanti-HCV, HBsAg and/or anti-HBcore screening.

  17. Leucopenia (Neutrophil count < 1,8x10^9/L)

  18. Thrombopenia (Platelets < 90x10^9/L)

  19. Elevated liver enzymes (>2x ULN)

  20. Abnormal renal function (eGFR< 30 mL/min)

  21. Other conditions which in the opinion of the investigator may interfere with thesubject's ability to comply with the study procedure

Study Design

Total Participants: 136
Study Start date:
November 01, 2016
Estimated Completion Date:
April 30, 2022

Study Description

Subjects will receive treatment with oral prednisone 40 mg/day for 2 weeks, followed by fixed tapering over 6 weeks. Half of the subjects will be randomized to concomitant 6-MP 1-1.5 mg/kg/day and half will receive concomitant placebo treatment. During the entire course of the trial all subjects will receive maintenance treatment with 5-ASA in an oral dose of at least 2 gram per day. Subjects will be subjected to one colonoscopy at baseline and one sigmoidoscopy in week 52 in order to assess endoscopic disease activity.

Data will be collected using electronic case report forms (eCRF) with Castor EDC. Quality and data validation procedures will be applied to ensure the validity and accuracy of the clinical database. Monitoring of the study will be done according to the GCP guidelines and following a monitoring plan. The financier of the study, ZonMw Goed Gebruik Geneesmiddelen, has the right to perform an audit if seen necessary.

Connect with a study center

  • Noordwest Ziekenhuisgroep

    Alkmaar,
    Netherlands

    Active - Recruiting

  • Flevoziekenhuis

    Almere,
    Netherlands

    Active - Recruiting

  • Meander MC

    Amersfoort, 3813 TZ
    Netherlands

    Active - Recruiting

  • Amstelland Hospital

    Amsterdam,
    Netherlands

    Active - Recruiting

  • Amsterdam UMC, location AMC

    Amsterdam, 1105AZ
    Netherlands

    Active - Recruiting

  • Amsterdam UMC, location VUMC

    Amsterdam, 1081 HZ
    Netherlands

    Active - Recruiting

  • OLVG Oost

    Amsterdam, 1090 HM
    Netherlands

    Active - Recruiting

  • MC Haaglanden

    Den Haag, 2512 VA
    Netherlands

    Active - Recruiting

  • Tergooi Hospital

    Hilversum, 1213 XZ
    Netherlands

    Active - Recruiting

  • Westfriesgasthuis

    Hoorn,
    Netherlands

    Active - Recruiting

  • St. Antonius Hospital

    Nieuwegein, 3435 CM
    Netherlands

    Active - Recruiting

  • Sint Franciscus Gasthuis

    Rotterdam,
    Netherlands

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.